Wave Life Sciences Receivables

Wave Life Sciences's receivables stands at $890K as of June 2026. That compares with $1.6M in the prior-year period — down 45.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Wave Life Sciences reported $890K in receivables versus $1.6M a year earlier — a 45.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.6M in the prior-year period — down 45.1% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Wave Life Sciences's receivables evolved across reporting periods, while the comparison chart places WVE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Wave Life Sciences's reading of $890K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.